



# Obesity therapies: Weighing the impact



Obesity is among the world's largest public health crises, with the number of impacted adults projected to jump 50% by 2030.

During the past year, treatment methods have rapidly evolved. There is heightened enthusiasm around prescription weight loss drugs, especially GLP-1 (glucagon-like peptide 1) medications, which were originally developed to treat Type II diabetes. GLP-1s<sup>1</sup> can regulate appetite and have emerged as a new generation of anti-obesity drugs after showing strong efficacy in helping non-diabetics lose weight.

So, what does the future hold for these medications, and what could the impact be on society, the economy, the healthcare sector, and more? The UBS Chief Investment Office (CIO) invites you to a deep-dive conversation with [Dr. Jamie Kane](#), Director, Northwell Health Center for Weight Management, and [Paul Donovan](#), Chief Economist, UBS Global Wealth Management, hosted by Anthony Pastore.

We encourage you to tune in on **Monday, October 2 at 12 p.m. CT.**

## [ATX Wealth Partners](#)

UBS Financial Services  
98 San Jacinto Blvd., Suite 600  
Austin, TX 78701

[atxwealthpartners@ubs.com](mailto:atxwealthpartners@ubs.com)



<sup>1</sup>GLP-1 (glucagon-like peptide 1) medications can stimulate insulin secretion and inhibit glucagon secretion, stomach emptying, and food intake.

Research from CIO GWM is provided by UBS Financial Services Inc. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. In Canada, research from CIO GWM is provided by UBS Investment Management Canada Inc.

The views expressed in the research provided do not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific individuals. They are based on numerous assumptions. Different assumptions could result in materially different results. We recommend that you obtain financial and/or tax advice as to the implications (including tax) prior to investing.

**Important information about brokerage and advisory services.**

As a firm providing wealth management services to clients, UBS Financial Services Inc. offers investment advisory services in its capacity as an SEC-registered investment adviser and brokerage services in its capacity as an SEC-registered broker-dealer. Investment advisory services and brokerage services are separate and distinct, differ in material ways and are governed by different laws and separate arrangements. It is important that you understand the ways in which we conduct business, that you carefully read the agreements and disclosures that we provide to you about the products or services we offer. For more information, please review the client relationship summary provided at [ubs.com/relationshipssummary](https://ubs.com/relationshipssummary), or ask your UBS Financial Advisor for a copy.

UBS Financial Services Inc.  
[ubs.com/fs](https://ubs.com/fs)

© UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved. UBS Financial Services Inc. is a subsidiary of UBS AG. Member FINRA/SIPC. UBS Financial Advisors are Registered Representatives of UBS Financial Services Inc.